Skip to main content

Table 1 Characteristic of 69 immunocompromised patients

From: Diagnostic value of metagenomic next-generation sequencing of bronchoalveolar lavage fluid for the diagnosis of suspected pneumonia in immunocompromised patients

Characteristic

69 patients

Age (year), mean ± SD

57 ± 15

Gender, male, n (%)

44(64)

Immunocompromised status, n (%)

 

 Hematologic malignancy

23(33)

 Solid-organ transplantation

14(20)

 Solid tumour receiving chemotherapy

5(7)

 Immunosuppressive therapya

21(30)

 Prolonged corticosteroid therapyb

33(48)

Disease severity

 

 PSI score, mean ± SD

127 ± 51

 Invasive mechanical ventilation, n (%)

22(32)

 Septic shock, n (%)

25(36)

Laboratory findings

 

 WBC (109/L), median (Q1, Q3)

6.58(4.93,11.05)

 Neutrophils (109/L), median (Q1, Q3)

5.66(3.23,9.39)

 Lymphocyte count (106/L), median (Q1, Q3)

0.73(0.35,1.17)

 PaO2/FiO2, mean ± SD

196 ± 98

 Albumin (g/L), mean ± SD

30 ± 7

Serum creatinine(mmol/L), median (Q1, Q3)

80(57, 127)

 LDH (U/L), median (Q1, Q3)

432(304, 726)

 CRP (mg/l), median (Q1, Q3)

88(42,149)

 PCT (ng/ml), median (Q1, Q3)

0.27(0.11,1.20)

outcome

 

 Total 30-day mortality, n (%)

14(20)

  1. PSI pneumonia severity index, WBC white blood cell, LDH lactate dehydrogenase, CRP C-reactive protein, PCT procalcitonin
  2. aMore than 2 weeks. Underlying diseases include Dermatomyositis (2), Leukemia (1), connective tissue diseases (6), Solid-organ transplantation (9), Hemophilia (1), Chronic nephritic syndrome (1), Thrombocytopenia (1)
  3. bDefined as > 0.3 mg/kg/d of prednisone-equivalent for ≥ 3 weeks. Underlying diseases include Dermatomyositis (1), Connective tissue diseases (9), Solid-organ transplantation (10), Hemophilia (1), Nephrotic syndrome (6), Thrombocytopenia (1), interstitial lung disease (1), Hematologic malignancy (2), Intracranial tumour (1), Dermatology (1)